Antabio, a Labège, France-based clinical stage biopharmaceutical company, raised €25M in Series B funding.
The round saw participation from AMR Action Fund, the EIC Fund, BNP Paribas Développement, Relyens Innovation Santé / Turenne Capital, IRDI Capital Investment and Christophe Ricard, the former President of OM Pharma.
The company intends to use the funds to support the clinical development of MEM-ANT3310, a next generation antibacterial combination currently in phase 1 trials.
Led by CEO and Founder Marc Lemonnier, Antabio is a clinical stage biopharmaceutical company developing novel and highly differentiated antibacterial treatments of drug-resistant infections as defined by the CDC and WHO’s critical priority pathogens, with a particular focus on life-threatening respiratory infections, including carbapenem-resistant nosocomial pneumonia and chronic pulmonary diseases. Its lead program, MEM-ANT3310, is being developed for the treatment of hospital-acquired infections such as nosocomial pneumonia caused by carbapenem-resistant Acinetobacter baumannii (CRAB) and carbapenem-resistant Enterobacterales (CRE). Antabio’s portfolio includes two further programs: 1) ANT3273, a groundbreaking, novel class, novel mode of action inhalation treatment of Pseudomonas aeruginosa (PA) infections, particularly those affecting patients with chronic pulmonary diseases (such as Bronchiectasis, Cystic Fibrosis and COPD); and 2) ANT2681, a novel and potent metallo beta-lactamase (MBL) inhibitor to be combined with meropenem for the treatment of MBL-producing carbapenem-resistant Enterobacterales (CRE), particularly New Delhi metallo-beta-lactamase (NDM) carrying strains.
FinSMEs
12/12/2023